This manuscript by Sternberg et al. reports on an unselected series of 87 consecutive patients presenting with advanced transitional cell carcinoma of the bladder. At presentation, all patients underwent clinical staging, which included a urinary cytology, CT scan and an extensive transurethral biopsy and/or resection (TURB). The purpose of this study was to determine if bladder preservation could be achieved without compromising cure. To accomplish this goal, the authors utilized a combination of neo-adjuvant M-VAC chemotherapy and either TURB alone or partial cystectomy. The endpoints of the study are progression free and total survival and the status of the patient's bladder.
Why was this study performed? It was performed because radical cystectomy is a major operative procedure that even when associated with the best possible reconstruction, neo-bladder, results in a significant alteration in patient quality of life. However, patient survival, quantity of life, is more important to most and we must be certain that any strategy designed to retain a patient's bladder does not compromise the cure of muscle invasive transitional cell cancer which has the potential to be a life limiting disease. It is important to note that since the goal of this study was to improve quality of life, this treatment philosophy does not need to demonstrate a survival advantage. It is only necessary to determine that survival is not being compromised. The reward is not quantity of life but quality of life. Obviously this phase II study can not and was not designed to address survival relative to other treatments; that can only be accomplished by a large, multi-institutional phase III study. This study is published to give us food for thought.
The most troubling aspect of this study is its reliance on neo-adjuvant M-VAC chemotherapy since the recently published MRC-EORTC neo-adjuvant CMV strategy realized only a modest (5.5% not statistically significant) improvement in overall survival [1] . However, in that study, patients were not treated with M-VAC and surgery, the operative mortality (3.7%) was unacceptably high, most patients in the immediate therapy arm received adjuvant chemotherapy at relapse and although there were statistically significant differences in metastasis free survival, the study was under powered to reach significance for the differences seen in overall survival. The soon to be released SWOG cystectomy alone vs. neo-adjuvant M-VAC plus cystectomy study should be a better comparison than the MRC-EORTC study and although the results are not yet known, I do not believe the MRC-EORTC study will close the door on neoadjuvant chemotherapy.
As with any study performed over time, there are a number of minor inconsistencies within this manuscript. In the methods, the authors state that any patient experiencing a post M-VAC clinical downstaging (defined as a decrease of at least two stage categories to T] or less) was considered a suitable candidate for bladder preservation. However, only 42 of the 67 patients satisfying this definition actually entered the bladder preservation arm of this study. In reality, patients with post M-VAC Tt disease were not considered candidates for bladder preservation. I agree with this caution because downstaging to T o has been repeatedly shown to be associated with an improved prognosis. A second point is that although the initial 87 patients were unselected, those entering bladder preservation 42 of 87 (48%) were highly selected and aggressively treated. One should not consider bladder preservation with M-VAC and nonradical surgery a treatment for all patients.
What has this study accomplished? First and foremost it has shown that this treatment may be appropriate for some patients. The overall five-year survival of 64% for the entire population is comparable to that seen in other reports of outcome in patients with advanced bladder cancer. Thirty-two of the eighty-seven patients, 36.8%, were able to retain their bladder and twenty-six of eighty-seven, 29.9% were able to do so with no evidence of disease recurrence. This was accomplished in 18 of 42 (42.9%) patients with TURB alone and in 8 of 13 (61.5%) with partial cystectomy. Although only 13 patients were treated with M-VAC plus partial cystectomy, the success rate of this strategy appears somewhat better than that achieved by TURB. This may indicate that partial cystectomy is a more reliable means of excising residual disease.
In summary, the authors have presented us with an alternative approach to the treatment of advanced bladder cancer. This approach allows for the selection of a subset of patients who may be able to retain a functioning bladder following neo-adjuvant M-VAC and aggressive local surgery. The overall survival appears to indicate that the outcome of those not deemed candidates for bladder preservation is not prejudiced. Ultimately, like all other postulated therapies, these results will need to be confirmed in multi-institutional, randomized phase III trials.
M. C. Benson Professor of Urology Columbia University College of Physicians & Surgeons;
Urologic Oncology Principal Investigator Southwest Oncology Group New York Presbyterian Hospital -Columbia Campus New York, NY, USA "It is a pleasure for me, but simultaneously difficult, to write a review of the 10th edition of Wintrobe's Clinical Hematology. I first became acquainted with this textbook about six years ago, when I received the 9th edition as a gift from my chief and colleagues at the Hematology Department in Basel-CH. I already owned a 'classical' textbook of Hematology but quickly understood that Wintrobe was something special. It was easier to read, easy to peruse for solutions to specific problems, and included more tables and illustrations to facilitate comprehension." The 10th edition is yet another large step forward! This new work has evolved in the ensuing decades from a single-to a multi-authored text. Many new chapters have been introduced. The first one concerns the laboratory of hematology with a clear explanation of immunodiagnostic, and flow cytometry with the different cluster of differentiation, the cytogenetic anomalies and molecular genetics. All of these with their clinical applications! The succeeding chapters on the normal hematologic system detail all of the different cellular compounds of peripheral blood on the basis of physiology and pathophysiology. The non-malignant disorders of red cells, coagulation and leukocytes are explained in the same manner: the use of a second colour (red) to brighten and clarify text-oriented pages facilitates the text. Every chapter is followed by an extensive reference list for readers who need details concerning a particular problem. The chapter on the hematologic malignancies is excellent: the individual groups of malignancies are preceded by a series of general chapters about principles of diagnosis, clinical complications, principles of therapy, immunotherapy, gene therapy and supportive care.
My opinion of this textbook is obvious by now!: Wintrobe's textbook of Hematology is the 'hematology Bible' and I recommend it to every onco-hematologist.
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